ID   Rh41-807R
AC   CVCL_8670
DR   Wikidata; Q54950359
RX   PubMed=20807811;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:88339; BMS-754807.
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line).
CC   Derived from site: Metastatic; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2176 ! Rh41
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 15
//
RX   PubMed=20807811; DOI=10.1158/0008-5472.CAN-10-0391;
RA   Huang F., Hurlburt W., Greer A., Reeves K.A., Hillerman S., Chang H.,
RA   Fargnoli J., Finckenstein F.G., Gottardis M.M., Carboni J.M.;
RT   "Differential mechanisms of acquired resistance to insulin-like growth
RT   factor-I receptor antibody therapy or to a small-molecule inhibitor,
RT   BMS-754807, in a human rhabdomyosarcoma model.";
RL   Cancer Res. 70:7221-7231(2010).
//